252 related articles for article (PubMed ID: 19204929)
1. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells.
Gaetano CG; Samadi N; Tomsig JL; Macdonald TL; Lynch KR; Brindley DN
Mol Carcinog; 2009 Sep; 48(9):801-9. PubMed ID: 19204929
[TBL] [Abstract][Full Text] [Related]
2. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis.
Samadi N; Gaetano C; Goping IS; Brindley DN
Oncogene; 2009 Feb; 28(7):1028-39. PubMed ID: 19079345
[TBL] [Abstract][Full Text] [Related]
3. Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis.
Li S; Wang B; Xu Y; Zhang J
Mol Cancer; 2011 Feb; 10():18. PubMed ID: 21314984
[TBL] [Abstract][Full Text] [Related]
4. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
[TBL] [Abstract][Full Text] [Related]
5. Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs.
North EJ; Osborne DA; Bridson PK; Baker DL; Parrill AL
Bioorg Med Chem; 2009 May; 17(9):3433-42. PubMed ID: 19345587
[TBL] [Abstract][Full Text] [Related]
6. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.
Zhang H; Xu X; Gajewiak J; Tsukahara R; Fujiwara Y; Liu J; Fells JI; Perygin D; Parrill AL; Tigyi G; Prestwich GD
Cancer Res; 2009 Jul; 69(13):5441-9. PubMed ID: 19509223
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid.
Inoue M; Xie W; Matsushita Y; Chun J; Aoki J; Ueda H
Neuroscience; 2008 Mar; 152(2):296-8. PubMed ID: 18280050
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest.
Samadi N; Bekele RT; Goping IS; Schang LM; Brindley DN
PLoS One; 2011; 6(5):e20608. PubMed ID: 21647386
[TBL] [Abstract][Full Text] [Related]
9. Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration.
Ptaszynska MM; Pendrak ML; Stracke ML; Roberts DD
Mol Cancer Res; 2010 Mar; 8(3):309-21. PubMed ID: 20197381
[TBL] [Abstract][Full Text] [Related]
10. ATX-LPA axis induces expression of OPN in hepatic cancer cell SMMC7721.
Zhang R; Zhang Z; Pan X; Huang X; Huang Z; Zhang G
Anat Rec (Hoboken); 2011 Mar; 294(3):406-11. PubMed ID: 21337710
[TBL] [Abstract][Full Text] [Related]
11. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid.
Kishi Y; Okudaira S; Tanaka M; Hama K; Shida D; Kitayama J; Yamori T; Aoki J; Fujimaki T; Arai H
J Biol Chem; 2006 Jun; 281(25):17492-17500. PubMed ID: 16627485
[TBL] [Abstract][Full Text] [Related]
12. Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells.
Zhang R; Wang J; Ma S; Huang Z; Zhang G
BMC Cell Biol; 2011 Mar; 12():11. PubMed ID: 21406114
[TBL] [Abstract][Full Text] [Related]
13. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.
Gupte R; Patil R; Liu J; Wang Y; Lee SC; Fujiwara Y; Fells J; Bolen AL; Emmons-Thompson K; Yates CR; Siddam A; Panupinthu N; Pham TC; Baker DL; Parrill AL; Mills GB; Tigyi G; Miller DD
ChemMedChem; 2011 May; 6(5):922-35. PubMed ID: 21465666
[TBL] [Abstract][Full Text] [Related]
14. Identification of large-scale molecular changes of Autotaxin(ENPP2) knock-down by small interfering RNA in breast cancer cells.
Noh JH; Ryu SY; Eun JW; Song J; Ahn YM; Kim SY; Lee SH; Park WS; Yoo NJ; Lee JY; Lee SN; Nam SW
Mol Cell Biochem; 2006 Aug; 288(1-2):91-106. PubMed ID: 16601922
[TBL] [Abstract][Full Text] [Related]
15. Novel point mutations attenuate autotaxin activity.
Koh E; Bandle RW; Roberts DD; Stracke ML; Clair T
Lipids Health Dis; 2009 Feb; 8():4. PubMed ID: 19222837
[TBL] [Abstract][Full Text] [Related]
16. Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors.
Xu X; Yang G; Zhang H; Prestwich GD
Prostaglandins Other Lipid Mediat; 2009 Sep; 89(3-4):140-6. PubMed ID: 19682598
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
[TBL] [Abstract][Full Text] [Related]
18. Murine and human autotaxin alpha, beta, and gamma isoforms: gene organization, tissue distribution, and biochemical characterization.
Giganti A; Rodriguez M; Fould B; Moulharat N; Cogé F; Chomarat P; Galizzi JP; Valet P; Saulnier-Blache JS; Boutin JA; Ferry G
J Biol Chem; 2008 Mar; 283(12):7776-89. PubMed ID: 18175805
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous stimulation of spinal NK1 and NMDA receptors produces LPC which undergoes ATX-mediated conversion to LPA, an initiator of neuropathic pain.
Inoue M; Ma L; Aoki J; Ueda H
J Neurochem; 2008 Dec; 107(6):1556-65. PubMed ID: 19014389
[TBL] [Abstract][Full Text] [Related]
20. Cyclic phosphatidic acid is produced by autotaxin in blood.
Tsuda S; Okudaira S; Moriya-Ito K; Shimamoto C; Tanaka M; Aoki J; Arai H; Murakami-Murofushi K; Kobayashi T
J Biol Chem; 2006 Sep; 281(36):26081-8. PubMed ID: 16837466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
